DataMEDS AI Acquires Helomics for $1.5M, Stock Surges 253% as Company Enters $40B Cancer Market

DataMEDS AI Completes Helomics Acquisition, Enters Oncology Market

DataMEDS AI acquired Helomics Corporation from Axe Compute Inc. (NASDAQ:AGPU) for a total purchase value of $1.5 million3

3

. The transaction, completed through common shares and an acquisition note, brought DataMEDS a CLIA/CAP-certified clinical laboratory, all equipment, the Predictive Oncology contract research organization central lab services business, and $1.5 million in cash3

3

. The acquired entity carries zero third-party debt and no outstanding accounts payable outside of regular monthly operating expenses2

2

. Helomics is a Pittsburgh-based functional precision medicine oncology platform that applies artificial intelligence to real-world tumor data to support drug discovery and cancer treatment decisions3

3

.

NASDAQ:MEDS Stock Surges 253% on Acquisition News

Shares of DataMEDS AI (NASDAQ:MEDS) jumped 66.04% to $2.68 in pre-market trading following the acquisition announcement4

4

, before surging 253.70% to $5.73 during Wednesday's trading session2

2

. The stock reached a new 52-week high, with DataMEDS maintaining a market capitalization of approximately $5 million4

4

. Gerald Commissiong, Interim Co-CEO of DataMEDS, stated: "We are thrilled to have completed this strategic transaction that thrusts DataMEDS into the field of oncology, where we know there is a tremendous need to improve patient outcomes, especially in rural areas"2

2

.

Strategic Entry Into $40 Billion Cancer Diagnostics Market

The Helomics acquisition marks DataMEDS AI's strategic expansion into the $40 billion U.S. cancer diagnostic and treatment market3

3

. This move broadens the company's clinical focus beyond GLP-1 agonist side-effect management and long COVID care into cancer diagnosis and treatment2

2

. Under DataMEDS' ownership, Helomics is expected to expand its capabilities beyond tumor molecular profiling and chemosensitivity testing, moving into cancer screening and molecular profiling, traditional CLIA/CAP-certified clinical laboratory services, and optimized nutritional support for cancer patients3

3

. The AI-powered cancer diagnostics laboratory represents the final operating business remaining from Axe Compute's former identity as Predictive Oncology Inc., prior to its name change in December 20253

3

.

New Corporate Website and Health Lives Here App Launch

Following the acquisition, DataMEDS AI launched its new corporate website www.DataMedsAI.com, reflecting an AI-centric marketing strategy designed to generate organic online traction1

1

. The website launch also follows a litigation settlement that eliminated approximately $19 million in liabilities from the company's balance sheet and retired 364,099 common shares1

1

. Commissiong noted: "With the previously disclosed closing of the Helomics Corporation acquisition and settlement of litigation related to the May 11, 2023 acquisition of Wellgistics, LLC., we are now poised to launch our Health Lives Here consumer application"1

1

. The company plans to soft launch the Health Lives Here app, which incorporates the artificial intelligence platform EinsteinRx and blockchain-enabled smart contracts platform PharmacyChain1

1

. The rebranding effort positions DataMEDS to challenge existing standards of care in difficult-to-treat chronic conditions through vertical integration of telemedicine, pharmacy, laboratory, and AI technologies3

3

.